Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology

"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PGNX)

Data from Pivotal Phase 2b Study of Progenics’ AZEDRA® (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium

GlobeNewswire October 4, 2017

Progenics Pharmaceuticals to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference

GlobeNewswire September 20, 2017

12 Biggest Mid-Day Gainers For Monday

Benzinga.com September 18, 2017

Biotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences

PR Newswire September 12, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharmaceuticals Inc. - PGNX

PR Newswire September 1, 2017

12 Biggest Mid-Day Losers For Friday

Benzinga.com September 1, 2017

Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge

Benzinga.com September 1, 2017

Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma

GlobeNewswire August 31, 2017

Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA®

GlobeNewswire August 31, 2017

Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update

GlobeNewswire August 9, 2017

Investor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call

Accesswire August 9, 2017

Breakfast Technical Briefing on Biotech Stocks -- Pacific Biosciences of California, Puma Biotechnology, PDL BioPharma, and Progenics Pharma

PR Newswire August 3, 2017

Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9

GlobeNewswire July 26, 2017

Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting

GlobeNewswire June 2, 2017

Progenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

GlobeNewswire June 1, 2017

Biotech Stocks on Investors' Radar -- Progenics Pharma, Dynavax Technologies, Intrexon, and Heat Biologics

PR Newswire May 12, 2017

Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update

GlobeNewswire May 4, 2017

Investor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call

Accesswire May 4, 2017

Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4

GlobeNewswire April 27, 2017

Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 20, 2017